首页> 外文OA文献 >Efficacy of Fondaparinux compared to Enoxaparin for Deep Vein Thrombosis Prophylaxis in Lower Extremity Orthopedic Surgery
【2h】

Efficacy of Fondaparinux compared to Enoxaparin for Deep Vein Thrombosis Prophylaxis in Lower Extremity Orthopedic Surgery

机译:Fondaparinux与依诺肝素相比在下肢骨科手术中预防深静脉血栓形成的功效

摘要

Background: Deep vein thrombosis (DVT) or venous thromboembolus (VTE), is a common complication with orthopedic surgery and remains a serious problem even with multiple medications available for prophylaxis. Enoxaparin and fondaparinux are widely accepted in North America, Australia, and Europe although, a lack of evidence still remains to determine which is more effective in DVT prophylaxis in orthopedic surgery. This systematic review seeks to determine whether fondaparinux is more effective than enoxaparin in DVT prophylaxis.Methods: A systematic literature search using multiple databases focusing on articles from professional journals, position statements, information from pharmaceutical manufacturers and CDC statistics were the primary sources for this study.Hypothesis: Fondaparinux is more effective than enoxaparin in DVT prophylaxis, with a lower bleeding risk, and reduction of patient death.Results: Six studies were evaluated to determine the effectiveness of fondaparinux compared to enoxaparin. Fondaparinux was compared to enoxaparin in double-blinded randomly assigned trials using subjects over 18 years of age who were scheduled to undergo orthopedic surgery of the lower extremity within 48 hours of admission. Potential subjects were excluded from the studies if they were involved in multiple trauma affecting more than one organ system, pregnancy, active bleeding, history of hemorrhagic stroke, bleeding disorder, hypersensitivity to heparin, serum creatinine above 2 mg/dl, and a platelet count below 100,000 per cubic millimeter. In all studies day 1 was defined as the day of surgery.Conclusion: Fondaparinux is more effective at DVT prophylaxis than enoxaparin and should be considered a preferential agent in high DVT risk orthopedic surgery. Further randomized trials with long term outcomes (u3e30 days), are needed to evaluate benefit to risk of longer term prophylaxis post orthopedic surgery.
机译:背景:深静脉血栓形成(DVT)或静脉血栓栓塞(VTE)是整形外科手术的常见并发症,即使使用多种预防药物,仍然是一个严重的问题。依诺肝素和磺达肝癸钠在北美,澳大利亚和欧洲已被广泛接受,尽管仍然缺乏确定哪一种在骨科手术中预防DVT更有效的证据。该系统评价旨在确定预防磺达肝素在DVT预防方面是否比依诺肝素更有效。方法:使用多个数据库进行系统的文献搜索,重点是专业期刊的文章,立场声明,制药企业的信息和CDC统计数据,是本研究的主要来源假设:在预防DVT方面,磺达肝癸钠比依诺肝素更有效,出血风险更低,并减少了患者的死亡。结果:评估了六项研究以确定磺达肝癸钠与依诺肝素的疗效。在18岁以上受试者的双盲随机分配试验中,将Fondaparinux与依诺肝素进行了比较,这些受试者计划在入院48小时内接受下肢骨科手术。如果潜在受试者参与多个器官系统,妊娠,活动性出血,出血性中风病史,出血性疾病,肝素过敏,血清肌酐高于2 mg / dl以及血小板计数的多处创伤,则将其排除在研究之外每立方毫米100,000以下。在所有研究中,第1天均定义为手术当天。结论:磺达肝癸钠在DVT预防上比依诺肝素更有效,在高DVT风险的骨科手术中应被视为优先药物。需要进一步的具有长期预后(≥30天)的随机试验来评估骨科手术后长期预防风险的益处。

著录项

  • 作者

    Fletcher Gregg A.;

  • 作者单位
  • 年度 2009
  • 总页数
  • 原文格式 PDF
  • 正文语种
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号